세계의 신장암 치료제 시장 : 암 유형별, 치료법별, 약물 종류별, 투여 경로별, 유통 채널별, 지역별, 기회 및 예측(2018-2032년)

Global kidney cancer drugs market is projected to witness a CAGR of 5.80% during the forecast period 2025-2032, growing from USD 7.02 billion in 2024 to USD 11.02 billion in 2032. The global kidney cancer drugs market experiences rapid growth, driven by a combination of aging population, advancement in therapeutic option and clinical factors. As per the American Cancer Society's estimates in 2024

around 81,610 new cases of kidney cancer (52,380 males and 29,230 females) are diagnosed and about 14,390 people (9,450 men and 4,940 women) died from this disease.

The kidney cancer drug market is seeing growth owing to several principal drivers. First, as the global population continues to age and lifestyle factors change, the incidence of kidney cancer is rising, with the number of patients in need of treatment also increasing. Most notably, the outcomes of patients have changed as evidence-based treatment options have improved significantly with the rise of immunotherapy, and targeted therapies as the most used treatment options. One of the main trends is a shift toward the use of extremely effective combination therapies, which are recognized as standard of care first line therapy.

Moreover, the extensive investment in Research and Development (R&D) is consistently evolving, resulting in a pipeline of innovative agents such as new classes of HIF-2a inhibitors. Also, with the ease of administration of oral therapies and an increased focus on individualized therapy based on molecular diagnostics, both majorly drive market development in a way that enhances the efficacy of treatment and promotes patient compliance. For instance, in February 2025, Telix Pharmaceuticals Limited declared that the FDA has approved and given priority consideration to the BLA of TLX250-CDx for the treatment of clear cell renal cell carcinoma (ccRCC).

Advancement in Diagnostic Technology

Developments in advanced diagnostic technologies are fundamentally driving growth in the global kidney cancer drugs market by creating more opportunities for early detection, better tumor characterization, and personalized treatment approaches. Advancements in imaging technologies such as AI-enriched CT/MRI and new PET-CT tracers enable the identification of smaller tumors that improve patient eligibility for systemic therapies. Additionally, liquid biopsies and genomic profiling enable the non-invasive detection of mutations and help to refine the use of targeted therapies and immunotherapy based on individual patient biomarkers. AI-enabled diagnostic platforms aim to optimize treatment selection based on prediction of drug responses on a given patient, which mitigates the burden of trial-and-error prescribing and allows for greater adoption of high-efficacy treatment regimens. Furthermore, sequential combination therapies, digitized multi-omics, and AI diagnostic capabilities will further attract patients and drive demand in new areas of precision medicine.

Additionally, leading research organizations are focusing on developing new technologies to improve the quality of care provided to the patient population. For instance, according to an article published in American Society of Clinical Oncology (ASCO) in February 2023, the Phase 3 ZIRCON trial assessed the use of Zr-DFO-girentuximab PET/CT imaging to detect and characterize clear-cell renal cell carcinoma (ccRCC).

Hospitals Holds Largest Distribution Channels of Drugs

There are various key factors contributing to the dominating position of hospitals segment in the kidney cancer drugs market. One reason is the treatment for kidney cancer may include complicated regimens in terms of dosage, handling, storage requiring special consideration, as well as requiring thorough ongoing monitoring of side effects, due to the use of immunotherapies and targeted therapies. Research suggests the complicated treatment regimen can be managed more effectively by hospital-based oncology departments with highly skilled doctors and specialty oncology pharmacists on staff as well as nursing staff. They provide a controlled setting for intravenous drug administration, administer possible drug interactions, and offer extensive patient education and support care. Moreover, the exorbitant prices of most new kidney cancer drugs most often require dispensing by hospital pharmacies, which also enjoy bulk purchasing power and established supply chains for repeated access to these potentially life-saving drugs for patients receiving intensive cancer treatment. For instance, in January 2024, Fox Chase Cancer Center invested in a new study to demonstrate that immune checkpoint inhibitor-based therapy (ICI), a form of immunotherapy, is an equally effective frontline therapy for Black and white patients with metastatic kidney cell carcinoma.

The expansion of the Asia-Pacific kidney Cancer Medication Market

The renal cancer drug market is spearheaded in the Asia-Pacific (APAC) region for many reasons, as examples, the increasing incident and prevalence of kidney cancer linked to aging and lifestyles has positively contributed to a larger patient pool. Additionally, growing investments in the healthcare infrastructure and increased public understanding have improved early detection and significant demand for newer treatments. Patients now have greater access to pricey new medicines thanks to APAC's robust economic growth, rising healthcare costs, and expanding insurance coverage. Personalized medicine, such as targeted treatments and immunotherapies, is a major focus in the region, as well as high R&D and pharma investment, propels the creation and adoption of innovative medicines, But APAC's market does come with significant challenges. The exorbitant price of new kidney cancer medicines is a major hurdle for most patients, affecting accessibility. Varying and sometimes complex regulatory approvals in different nations have the potential to slow market access for innovative drugs.

Additionally, for market expansion in Asia-Pacific region in March 2025 companies like HUTCHMED (China) Limited and Innovent Biologics,Inc. jointly announced that FRUSICA-2 phase II/III clinical trial study in China for advanced renal cell carcinoma.

Impact of U.S. Tariffs on Kidney Cancer Drugs Market

The impact from recent the recent U.S. tariffs which targeted pharmaceutical import from China and India and other major suppliers. The tariffs cause an increase in production expenses which might raise drugs prices while creating potential disruptions in the supply chains. The thin profits margin of generic drugs manufacturer would intensify because of these added expenses which could lead to decreased competition and reduced treatment options. The global pharmaceutical export market faces economic trouble because of challenging condition in Ireland and South Korea. The possibility of companies moving manufacturing operation back to the United States may create temporary drugs shortages that will affect patient worldwide by disrupting their access to treatment and negatively impacts their outcomes.

Key Players Landscape and Outlook

There is an intense competition in the kidney cancer drugs market from established pharmaceutical companies and new start-up biotech firms involved in research and development. Additionally, the kidney cancer drugs market is projected to continue to grow in part due to new advances in immunotherapy, targeted therapy and increased combination or multi-modality regimens. The focus on more effective treatments with personalization and improved safety profiles will continue to enable patient improvements and quality of life. Companies like Novartis AG and Merck & Co., Inc. are continuously working on new innovation for the renal cell treatment.

According to the news published on Clinical trials Arena in October 2024, Arcus Biosciences Inc. announced a clinical trial collaboration with AstraZeneca plc to evaluate the combination of casdatifan (AB521) and volrustomig in ccRCC patients. Casdatifan is an investigational HIF-2a inhibitor from Arcus and volrustomig is an investigational PD-1/CTLA-4 bispecific antibody from AstraZeneca.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Kidney Cancer Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Cancer Type
    • 5.2.1.1. Renal Cell Carcinoma (RCC)
    • 5.2.1.2. Transitional Cell Cancer (TCC)
    • 5.2.1.3. Wilms Tumor (Nephroblastoma)
    • 5.2.1.4. Others
  • 5.2.2. By Therapy
    • 5.2.2.1. Targeted Therapy
    • 5.2.2.2. Immunotherapy
    • 5.2.2.3. Chemotherapy
    • 5.2.2.4. Other Therapies
  • 5.2.3. By Drug Class
    • 5.2.3.1. Anti-Angiogenesis
    • 5.2.3.2. Monoclonal Antibodies
    • 5.2.3.3. mTOR Inhibitors
    • 5.2.3.4. Interleukins
    • 5.2.3.5. Other Drug Classes
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Intravenous
    • 5.2.4.3. Subcutaneous
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital
    • 5.2.5.2. Specialty and Retail Pharmacies
    • 5.2.5.3. Others
  • 5.2.6. By Region
    • 5.2.6.1. North America
    • 5.2.6.2. Europe
    • 5.2.6.3. Asia-Pacific
    • 5.2.6.4. South America
    • 5.2.6.5. Middle East and Africa
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Cancer Type
  • 5.3.2. By Therapy
  • 5.3.3. By Drug Class
  • 5.3.4. By Route of Administration
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. North America Kidney Cancer Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Cancer Type
    • 6.2.1.1. Renal Cell Carcinoma (RCC)
    • 6.2.1.2. Transitional Cell Cancer (TCC)
    • 6.2.1.3. Wilms Tumor (Nephroblastoma)
    • 6.2.1.4. Others
  • 6.2.2. By Therapy
    • 6.2.2.1. Targeted Therapy
    • 6.2.2.2. Immunotherapy
    • 6.2.2.3. Chemotherapy
    • 6.2.2.4. Other Therapies
  • 6.2.3. By Drug Class
    • 6.2.3.1. Anti-Angiogenesis
    • 6.2.3.2. Monoclonal Antibodies
    • 6.2.3.3. mTOR Inhibitors
    • 6.2.3.4. Interleukins
    • 6.2.3.5. Other Drug Classes
  • 6.2.4. By Route of Administration
    • 6.2.4.1. Oral
    • 6.2.4.2. Intravenous
    • 6.2.4.3. Subcutaneous
  • 6.2.5. By Distribution Channel
    • 6.2.5.1. Hospital
    • 6.2.5.2. Specialty and Retail Pharmacies
    • 6.2.5.3. Others
  • 6.2.6. By Country Share
    • 6.2.6.1. United States
    • 6.2.6.2. Canada
    • 6.2.6.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Kidney Cancer Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.1.1. Renal Cell Carcinoma (RCC)
        • 6.3.1.2.1.2. Transitional Cell Cancer (TCC)
        • 6.3.1.2.1.3. Wilms Tumor (Nephroblastoma)
        • 6.3.1.2.1.4. Others
      • 6.3.1.2.2. By Therapy
        • 6.3.1.2.2.1. Targeted Therapy
        • 6.3.1.2.2.2. Immunotherapy
        • 6.3.1.2.2.3. Chemotherapy
        • 6.3.1.2.2.4. Other Therapies
      • 6.3.1.2.3. By Drug Class
        • 6.3.1.2.3.1. Anti-Angiogenesis
        • 6.3.1.2.3.2. Monoclonal Antibodies
        • 6.3.1.2.3.3. mTOR Inhibitors
        • 6.3.1.2.3.4. Interleukins
        • 6.3.1.2.3.5. Other Drug Classes
      • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.4.1. Oral
        • 6.3.1.2.4.2. Intravenous
        • 6.3.1.2.4.3. Subcutaneous
      • 6.3.1.2.5. By Distribution Channel
        • 6.3.1.2.5.1. Hospital
        • 6.3.1.2.5.2. Specialty and Retail Pharmacies
        • 6.3.1.2.5.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Kidney Cancer Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Kidney Cancer Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Kidney Cancer Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Kidney Cancer Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Amgen Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Pfizer Inc.
  • 21.3.3. Novartis AG
  • 21.3.4. Cipla Ltd.
  • 21.3.5. F. Hoffmann-La Roche AG
  • 21.3.6. Bayer AG
  • 21.3.7. Exelixis, Inc.
  • 21.3.8. Bristol-Myers Squibb Company
  • 21.3.9. Merck & Co., Inc.
  • 21.3.10. UroGen Pharma Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer